Recommended counseling for newly diagnosed chronic hepatitis B virus (HBV) patients (i.e., hepatitis B surface antigen [HBsAg]-positive for >6 months) includes education regarding measures to minimize the risk of inadvertent HBV transmission and promotion of healthy lifestyle habits.1, 2 In addition, a review of the patient's current and past medical history, HBV replication status, and liver disease severity allows one to better estimate the risk of developing progressive liver disease and hepatocellular carcinoma (HCC). These data also help the clinician determine the need and type of potential antiviral therapy and subsequent frequency and type of disease monitoring.
Recommended Testing for Patients with Chronic HBV
The physical examination in chronic HBV patients should include an assessment for spider angioma, gynecomastia, and splenomegaly, which are indicative of more advanced liver disease. An assessment of the route (vertical versus horizontal) and duration of infection, family history of cirrhosis and HCC, alcohol and smoking habits, and current medication and herbal product use should be undertaken (Table 1). Although prothrombin time and bilirubin are normal in most outpatients with chronic HBV, serial assessment of serum aminotransferase (i.e., aspartate aminotransferase and alanine aminotransferase [ALT]) levels can help determine the current status of infection. In addition, a complete blood count can help detect thrombocytopenia, which is an early marker of portal hypertension. Chronic HBV patients should be screened for concomitant hepatitis C virus, hepatitis D virus, and human immunodeficiency virus coinfection. Finally, a baseline serum alpha-fetoprotein level and liver ultrasound is recommended to screen for early stage HCC, radiographic stigmata of cirrhosis, and other causes of liver disease.2
|History and physical examination|
|Education to reduce transmission|
|Test/vaccinate household and sexual contacts|
|Minimize alcohol and smoking|
|Family history of HCC/cirrhosis|
|Assess body mass index|
|Serum AST/ALT, albumin, bilirubin, INR, complete blood count, platelet count|
|HBeAg, anti-HBe, quantitative HBV DNA level|
|Exclude HCV, HDV, HIV coinfection|
|Serum AFP and liver ultrasound|
|EGD if portal hypertension suspected to excluded varices|
|Minimize alcohol consumption|
|Balanced diet and exercise to reduce insulin resistance/hepatic steatosis|
|Acetaminophen analgesics <4 g/day preferred over NSAIDs/aspirin|
|Use of steroids/immunosuppressants/chemotherapy requires prophylactic oral antiviral|
|Normal ALT, HBV DNA >106 IU/mL|
|No immediate therapy|
|ALT every 3-6 months, then every 6 months|
|HBV DNA every 6 months|
|Immune active (HBeAg-positive)|
|Increased ALT, HBV DNA >2 × 104 IU/mL|
|ALT and HBV DNA every 3-4 months|
|Immune active (HBeAg-negative)|
|Increased ALT, HBV DNA >2 × 103 IU/mL|
|ALT and HBV DNA every 3-4 months|
|Inactive carrier (HBeAg-negative)|
|Normal or near normal ALT, HBV DNA low or undetectable|
|No immediate therapy|
|ALT and HBV DNA every 6-12 months|
|Treat if reactivation/disease flare detected|
HBV Replication Markers and Disease States
Laboratory markers of HBV replication include serum hepatitis B e antigen (HBeAg), anti-HBe, and quantitative HBV DNA levels. Most HBV DNA assays are based on polymerase chain reaction amplification with a lower limit of detection of 10 to 50 IU/mL and a 4 to 5 log 10 dynamic range, while assays using real-time polymerase chain reaction have improved sensitivity and have a greater dynamic range (8-9 log10). Quantification of HBV DNA at initial diagnosis and periodically thereafter in conjunction with serum ALT levels obtained on three or more occasions can help categorize disease stage and guide antiviral treatment decisions (Fig. 1). For example, immune tolerant patients that are HBeAg-positive with persistently high HBV DNA (>106 IU/mL) but normal ALT levels can defer antiviral therapy and be observed with serial laboratory measurements. In contrast, immune active HBeAg-positive patients with serum ALT levels persistently >2 times the upper limit of normal (ULN) and HBV DNA >20,000 IU/mL and HBeAg-negative patients with similar ALT elevations and HBV DNA >2,000 IU/mL should be considered for immediate antiviral therapy.2 After spontaneous HBeAg seroconversion to anti-HBe positivity, most inactive carriers remain HBeAg-negative with low or undetectable HBV DNA and normal or near normal serum ALT levels. However, up to 30% of these patients may develop a spontaneous disease reactivation that requires antiviral therapy, highlighting the need for indefinite laboratory and clinical monitoring of all untreated chronic HBV patients.3
HBV Genotypes and Precore/Core Promoter Variants
There are eight HBV genotypes labeled A through H that differ in their nucleotide sequence throughout the HBV genome (Table 2).4 In one multicenter study of 694 patients in the United States, a broad distribution of HBV genotypes was reported with genotypes A (35%) and D (10%), identified mostly in Caucasians and African Americans, whereas genotypes B (22%) and C (31%) predominated in Asian Americans.5 HBV genotypes may play an important role in disease progression and potential response to interferon (IFN) therapy. For example, Asian patients with HBV genotype B have earlier spontaneous HBeAg seroconversion and a better response to IFN therapy compared with patients with genotype C.6 In addition, the rate of disease progression and lifetime risk of HCC appears to be greater with untreated HBV genotype C > B.7 Similarly, Caucasian HBV patients with genotype A are most responsive to IFN therapy, with a 40% to 50% likelihood of HBeAg seroconversion. However, HBV genotypes are not associated with the likelihood of response to oral antiviral agents. Therefore, most experts do not recommend testing for HBV genotype in routine clinical practice unless IFN therapy is being considered.
|HBV Genotype||Frequency of Variants||Location||Clinical Significance|
|A||Low||High||North America, Europe, Central Africa||Highest response to IFN|
|B||High||Low||China, Japan, Korea, Asia||Earlier HBeAg seroconversion; increased IFN response compared with genotype C|
|C||Low||High||China, Japan, Korea, Asia||Delayed HBeAg seroconversion; increased risk of HCC|
|D||High||High||The Mediterranean, Middle East, South Asia||Most are HBeAg-negative|
|F||Low||ND||South and Central America|
|G||High||ND||United States, France|
|H||ND||ND||Mexico, South America|
Patients with active and inactive HBeAg-negative liver disease frequently harbor viral variants that lead to reduced expression of HBeAg in the serum.8 Precore variants that arise due to a point mutation at G1896A in the precore region and core promoter variants are frequently detected during spontaneous and treatment-induced HBeAg seroconversion. One large study suggested that the presence of core promoter and precore variants may increase the risk of HCC among untreated Taiwanese men with long-standing chronic HBV.7 Although commercial assays are available, most experts do not recommend testing for precore and core promoter variants due to their dynamic status and uncertain clinical significance.
Quantitative HBsAg Levels
Quantitative HBsAg levels are being studied in relationship to the natural history of chronic HBV and response to antiviral therapy.9 Serum quantitative HBsAg levels largely reflect the extent of host immune control over HBV replication. The dynamic range of available HBsAg assays vary from 0.1 to 1,000 IU/mL with serial dilutions possible from high titer samples. Quantitative HBsAg levels correlate positively with quantitative HBV DNA levels, and the correlation appears to be more consistent in HBeAg-positive patients compared with HBeAg-negative patients and inactive carriers. Retrospective studies suggest that lower baseline HBsAg levels in untreated patients are associated with a higher rate of spontaneous HBsAg seroconversion and lower risk of HCC. Baseline and on-treatment changes in HBsAg levels also may prove to be a more reliable and sensitive predictor of sustained response to IFN and oral antiviral therapy. However, additional prospective studies that account for HBV genotype, HBV DNA level, and HBeAg status are needed to determine the role of HBsAg quantification in individualizing the type and duration of treatment for chronic HBV.
Liver Biopsy and Noninvasive Staging Methods
A liver biopsy in a patient with viral hepatitis provides important objective information on the severity of liver inflammation as well as the stage of fibrosis. A liver biopsy can also help identify concomitant disease processes such as hepatic steatosis or steatohepatitis, which may increase the risk of liver disease progression. Therefore, a liver biopsy may influence the decision to treat a patient if more disease is noted than suspected based on serum ALT and HBV DNA levels. In addition, because the risk of HCC and disease progression is markedly higher in patients with bridging fibrosis and cirrhosis, monitoring and surveillance strategies may be altered. However, it should be noted that most experts do not believe that a liver biopsy is required prior to initiating antiviral therapy unless there is clinical uncertainty regarding the severity of liver disease. In addition, the limitations of liver biopsy with regard to understaging hepatic fibrosis, sampling artifact, and the procedural risk need to be considered.
Panels of serum fibrosis markers that reflect the extent of hepatic fibrogenesis, fibrolysis, and liver apoptosis have been proposed to noninvasively assess disease stage in chronic HBV.10 However, their specificity and reliability may be more limited in chronic HBV patients that frequently experience bursts of viral replication and liver necroinflammation that can lead to false positive test results. Liver elastography is a new noninvasive imaging modality wherein an external transducer is placed against the right costal margin and the speed of shear wave propagation reflects the extent of liver stiffness that is proportional to the extent of hepatic fibrosis.11 Studies of liver elastography in chronic HBV patients have demonstrated a good positive predictive value for detection of cirrhosis, but the presence of high serum ALT can lead to false positive test results. In particular, chronic HBV patients with a spontaneous surge in viral replication (high HBV DNA) and liver necroinflammation (high serum ALT) may have transient increases in liver stiffness that reflect inflammation rather than fibrosis. Furthermore, measurement of liver elastography can be technically difficult and less accurate in overweight and obese patients. Magnetic resonance elastography is another promising modality that samples a larger volume of tissue but requires further study.
All newly diagnosed chronic HBV patients should undergo a complete history, physical assessment, and laboratory assessment in an effort to assess the severity of liver disease and potential need for antiviral therapy. Counseling to reduce transmission and maintaining a healthy lifestyle are recommended to minimize the influence of environmental cofactors associated with liver disease progression. Markers of HBV replication (HBeAg, HBV DNA) along with serum ALT levels should be obtained initially and periodically thereafter to assess the state of HBV infection. A liver ultrasound is recommended in all newly diagnosed chronic HBV patients to assess for unsuspected liver masses, splenomegaly, and a nodular liver suggestive of advanced fibrosis or portal hypertension, which would influence decisions regarding treatment and monitoring. In addition, serial serum alpha-fetoprotein and ultrasound imaging is recommended for chronic HBV patients at increased risk of developing HCC based upon their disease state, demographic features, and medical history. Newer noninvasive modalities such as liver elastography may play a future role in assessing disease severity, but liver biopsy is currently recommended in cases of diagnostic uncertainty.